AZUSA, CA -- (MARKET WIRE) -- March 21, 2007 -- In January of this year Viral Genetics (OTCBB: VRAL) announced that it had preliminarily identified two peptides as the active components of its HIV/AIDS drug candidate, VGV-1, and further stated its follow up plan to confirm the findings. This research is important because identification of the active components should allow the Company to pursue studies aimed at enhancing the antiviral results of VGV-1, which is a significant development in moving VGV-1 forward as a HIV/AIDS therapy. This enhancement or “optimization” process would be accomplished largely through identifying the components’ mechanism of action and studying how different concentrations of the components influence the antiviral effects.
